PAD-2-mediated citrullination of nucleophosmin provides an effective target for tumor immunotherapy.
Ruhul H ChoudhuryPeter SymondsSamantha J PastonIan DanielsKatherine W CookMohamed GijonRachael L MetheringhamVictoria A BrentvilleLindy G DurrantPublished in: Journal for immunotherapy of cancer (2022)
This study indicates PAD2 can citrullinate the nuclear antigen NPM at position 277 which can be targeted by CD4 T cells for antitumor therapy. This is distinct from PAD4 citrullination of arginine 197 within NPM which results in its transport from the nucleoli to the nucleoplasm.